

**Subject: Specialised Services Circular (SSC 2616)**  
**Sent on behalf of: Chair of the SW Specialised Service Circular Group**

Dear Colleagues,

Please find attached the following Specialised Services Circular(s):

<b>SSC Number</b>	<b>SSC Title</b>	<b>Trusts approved to prescribe in accordance with the SSC, providing appropriate internal governance arrangements are in place</b>
2616	Provider Letter - End of 2023-24 RSV season and cessation of access to palivizumab	All South West Acute Trusts

**Is an implementation plan required from all SW trusts (regardless of commissioned status) for this SSC? No**

**For all other South West region trusts this is for information only.**

Trusts should ensure that use is registered on the Blueteq system (if appropriate).

Treatment will only be funded where the drugs minimum dataset is fully and accurately populated.

Please direct any queries to: [england.speccomm-southwest@nhs.net](mailto:england.speccomm-southwest@nhs.net)

Classification: Official

Publication reference:



England  
South West

Specialised Commissioning South West  
NHS England  
360 Bristol  
Marlborough Street  
Bristol  
BS1 3NX

Email: [england.speccomm-southwest@nhs.net](mailto:england.speccomm-southwest@nhs.net)

9 February 2024

**All Chief Executives**

**All Medical Directors**

**All Chief Pharmacists**

Dear Colleagues,

**End of 2023-24 Respiratory Syncytial Virus (RSV) season and cessation of access to palivizumab passive immunisation against RSV in at risk pre-term infants**

The Palivizumab National Expert Working Group, which includes JCVI representation, has reviewed the RSV situation in England and the rest of the United Kingdom closely. Current trends reflect a reduction in RSV positivity and hospitalisations due to RSV. RSV activity this season has, to date, reflected seasonal patterns observed before the Covid-19 pandemic.

**The Group therefore support cessation of the provision of palivizumab at the end of February 2024 unless changes are observed over the next month. Doses of palivizumab planned beyond February 2024 should *not* be given.**

I would be grateful if you could cascade this information to relevant clinical teams within your organisation to support the consistent adoption of the policy nationally.

Yours sincerely,

Luke Culverwell  
Deputy Director of Specialised  
Commissioning

Tracey Williams  
Principal Pharmacist